These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29765222)

  • 41. Effect of Urate-lowering Therapy on the Risk of Cardiovascular Disease and All-cause Mortality in Patients with Gout: A Case-matched Cohort Study.
    Chen JH; Lan JL; Cheng CF; Liang WM; Lin HY; Tsay GJ; Yeh WT; Pan WH
    J Rheumatol; 2015 Sep; 42(9):1694-701. PubMed ID: 26077411
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quality of care in gout: a clinical audit on treating to the target with urate lowering therapy in real-world gout patients.
    Janssen CA; Jansen TLTA; Oude Voshaar MAH; Vonkeman HE; van de Laar MAFJ
    Rheumatol Int; 2017 Sep; 37(9):1435-1440. PubMed ID: 28748426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A survey of the assessment and management of gout in general practitioners and medical officers within the Illawarra Network, Australia.
    Terrill M; Riordan J
    Int J Rheum Dis; 2017 Aug; 20(8):990-995. PubMed ID: 27153502
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How Can We Improve Disease Education in People with Gout?
    Fields TR; Batterman A
    Curr Rheumatol Rep; 2018 Mar; 20(3):12. PubMed ID: 29516200
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A qualitative study to explore health professionals' experience of treating gout: understanding perceived barriers to effective gout management.
    Humphrey C; Hulme R; Dalbeth N; Gow P; Arroll B; Lindsay K
    J Prim Health Care; 2016 Jun; 8(2):149-56. PubMed ID: 27477557
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic factors associated with early gout flare recurrence in patients initiating urate-lowering therapy during an acute gout flare.
    Janssen CA; Oude Voshaar MAH; Ten Klooster PM; Vonkeman HE; van de Laar MAFJ
    Clin Rheumatol; 2019 Aug; 38(8):2233-2239. PubMed ID: 31030363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Knowledge and practice in the management of asymptomatic hyperuricemia among primary health care physicians in Jeddah, Western Region of Saudi Arabia.
    Alqarni NA; Hassan AH
    Saudi Med J; 2018 Dec; 39(12):1218-1225. PubMed ID: 30520504
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rationale and design of the randomized evaluation of an Ambulatory Care Pharmacist-Led Intervention to Optimize Urate Lowering Pathways (RAmP-UP) Study.
    Coburn BW; Cheetham TC; Rashid N; Chang JM; Levy GD; Kerimian A; Low KJ; Redden DT; Bridges SL; Saag KG; Curtis JR; Mikuls TR
    Contemp Clin Trials; 2016 Sep; 50():106-15. PubMed ID: 27449546
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Barriers to Care in Gout: From Prescriber to Patient.
    Vaccher S; Kannangara DR; Baysari MT; Reath J; Zwar N; Williams KM; Day RO
    J Rheumatol; 2016 Jan; 43(1):144-9. PubMed ID: 26568590
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Illness perceptions in patients with gout and the relationship with progression of musculoskeletal disability.
    Dalbeth N; Petrie KJ; House M; Chong J; Leung W; Chegudi R; Horne A; Gamble G; McQueen FM; Taylor WJ
    Arthritis Care Res (Hoboken); 2011 Nov; 63(11):1605-12. PubMed ID: 22034122
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Achieving serum urate targets in gout: an audit in a gout-oriented rheumatology practice.
    Corbett EJM; Pentony P; McGill NW
    Int J Rheum Dis; 2017 Jul; 20(7):894-897. PubMed ID: 28205336
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New and Pipeline Drugs for Gout.
    Keenan RT; Schlesinger N
    Curr Rheumatol Rep; 2016 Jun; 18(6):32. PubMed ID: 27097819
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Significance of the initiation time of urate-lowering therapy in gout patients: A retrospective research.
    Feng X; Li Y; Gao W
    Joint Bone Spine; 2015 Dec; 82(6):428-31. PubMed ID: 26456042
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of hyperuricemia, gout and other crystalline arthritidies.
    Lioté F
    Reumatismo; 2012 Jan; 63(4):276-83. PubMed ID: 22303534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Physician adherence to ACR gout treatment guidelines: perception versus practice.
    Oderda GM; Shiozawa A; Walsh M; Hess K; Brixner DI; Feehan M; Akhras K
    Postgrad Med; 2014 May; 126(3):257-67. PubMed ID: 24918810
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evolution of management of gout: a comparison of recent guidelines.
    Khanna PP; FitzGerald J
    Curr Opin Rheumatol; 2015 Mar; 27(2):139-46. PubMed ID: 25611299
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dyslipidemia, Alcohol Consumption, and Obesity as Main Factors Associated With Poor Control of Urate Levels in Patients Receiving Urate-Lowering Therapy.
    Latourte A; Bardin T; Clerson P; Ea HK; Flipo RM; Richette P
    Arthritis Care Res (Hoboken); 2018 Jun; 70(6):918-924. PubMed ID: 28834411
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Gout.
    Dalbeth N; Merriman TR; Stamp LK
    Lancet; 2016 Oct; 388(10055):2039-2052. PubMed ID: 27112094
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The safety of treatment options available for gout.
    Schlesinger N
    Expert Opin Drug Saf; 2017 Apr; 16(4):429-436. PubMed ID: 28095258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.